Short-term recombinant human growth hormone treatment increases growth rate in achondroplasia

Journal of Clinical Endocrinology and Metabolism

Volumn 81, Issue 11, 1996, Pages 4033-4037

  Shohat, M ^a,c   Tick, D ^b   Barakat, S ^a   Bu, X ^a   Melmed, S ^a   Rimoin, D L ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c TEL AVIV UNIVERSITY   (Israel)

^d CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT GROWTH HORMONE;

ACHONDROPLASIA; ARTICLE; BONE DEVELOPMENT; BONE DYSPLASIA; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; GROWTH RATE; GROWTH REGULATION; HORMONAL THERAPY; HUMAN; HUMAN CELL; HUMAN TISSUE; LEG LENGTH INEQUALITY; MALE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ACHONDROPLASIA; BODY CONSTITUTION; BONE DEVELOPMENT; CHILD; CHILD, PRESCHOOL; FEMALE; GROWTH; HUMAN GROWTH HORMONE; HUMANS; MALE; TIME FACTORS;

EID: 0029794956     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.81.11.4033     Document Type: Article

References (16)

1. Rimoin DL, Lachman RS. 1993 Genetic disorders of the osseous skeleton. In: Brighton P, ed. McKusick's heritable disorders of connective tissue. New York: Mosby; 557-689.
2. Horton WA, Rotter JI, Rimoin DL, Scott CI, Hall JG. 1978 Standard growth curves of achondroplasia. J Pediatr. 93:435-438.
3. Shiang R, Rhompson LM, Zhu YZ, et al. 1994 Mutations in the transmembrane domain of FGFR-3 cause the most common genetic form of dwartism, achondroplasia. Cell. 78:335-342.
4. Rosenfeld RG, Frane J, Attie KM et al. 1989 Six-year results of a randomized, prospective trial of human growth hormone and oxandrolone in Turner syndrome. J. Pediatr. 121: 49-55.
5. Bierich JR. 1989 Growth hormone therapy in short children without classical growth hormone deficiency. J Endocrinol Invest 12(8 Suppl 3:25-33.
6. Torrado C, Bastian W, Wismiewski KE, Castells R. 1991 Treatment of children with Down's syndrome and growth retardation with recombinant human growth hormone. J Pediatr. 119:478-483.
7. Hopwood NJ, Hintz RL, Gertner JM, et al. 1993 Growth response of children with non-growth hormone deficiency and marked short stature during three years of growth hormone therapy. J Pediatr. 123:215-222.
8. Albanese A, Stanhope R. 1993 Growth and metabolic data following growth hormone treatment of children with intrauterine growth retardation. Horm Res. 39:8-12.
9. Ahmed ML, Foot AB, Edge JA. 1991 Noonan's syndrome: abnormalities of the growth hormone/IgF1 axis and the response to treatment with human biosynthetic growth hormone. Acta Paediatr. 80:446-450.
10. Darendeliler F, Hindmarsh PC, Brook CG. 1990 Non-conventional use of growth hormone: European experience. Horm Res. 33:128-136.
11. Horton WA, Hecht JT, Hood OJ, Mashall RN, Moore WV, Hollowell JG. 1992 Growth hormone therapy in achondroplasia. Am J Med Genet. 42:667-670.
12. Yamata T, Kanzaki S, Tanaka H, et al. 1993 Growth hormone (GH) treatment in achondroplasia. J Pediatr Endocrinol. 6:45-52.
13. Appan S, Laurent S, Chapman M, Hindmarsh PC, Brook CGD. 1990 Growth and growth hormone therapy in hypochondroplasia. Acta Paediatr. 79:796-803.
14. Nishi Y, Kajiyama M, Miyagawa S, Fujiwara M, Harmamoto K. 1993 Growth hormone therapy in achondroplasia. Acta Endocrinol (Copenh). 128:394-396.
15. Kodama H, Okabe I, Yanagisawa M. 1990 Therapeutic benefit of growth hormone in achondroplastic dwarfism. Acta Paediatr Jpn. 32:323-324.
16. Hecht JT, Horton WA, Reid CS, et al. 1989 Growth of the foramen magnum in achondroplasia. Am J Med Genet. 32: 528-535.